Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies

Archives of Neurology

Volumn 64, Issue 9, 2007, Pages 1331-1333

  Krumbholz, Markus ^a   Pellkofer, Hannah ^a   Gold, Ralf ^b   Hoffmann, Lisa Ann ^a   Hohlfeld, Reinhard ^a   Kümpfel, Tania ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; MITOXANTRONE; NATALIZUMAB; NEUTRALIZING ANTIBODY; PREDNISOLONE; STEROID;

ADULT; ALLERGY; ARTICLE; CASE REPORT; DELAYED HYPERSENSITIVITY; DEMYELINATING DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; REMISSION; REPEATED DRUG DOSE; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; DRUG HYPERSENSITIVITY; EDEMA; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; GAIT ATAXIA; GLUCOCORTICOIDS; HUMANS; HYPERSENSITIVITY, DELAYED; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SERUM SICKNESS;

EID: 34548602366     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.9.1331     Document Type: Article

References (9)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
2. Phillips JT, O'Connor PW, Havrdova E, et al. Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology. 2006;67(9):1717-1718.
3. Miller DH, Khan OA, Sheremata WA, et al; International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348(1):15-23.
4. Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infliximab. J Emerg Med. 2006;30(1):41-44.
5. Schutgens RE. Rituximab-induced serum sickness. Br J Haematol. 2006;135(2):147.
6. Blisard D, Nation D, Khan A, et al. Serum sickness in pancreas transplantation with campath-1h induction. Am J Transplantation. 2006;82(1)(suppl 6):528.
7. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126(1):19-31.
8. Vollmer TL, Phillips JT, Goodman AD, et al. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis. Mult Scler. 2004;10(5):511-520.
9. Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS: The UK Antegren Study Group. Neurology. 1999;53(3):466-472.